… between the encouraging results of the randomized phase II trial of carboplatin/… randomized
phase III trial? The most likely explanation is that the smaller sample size of the phase II trial …

… In the present trial, we used a randomized phase II design in chemonaive patients with
locally advanced or metastatic NSCLC to simultaneously evaluate the activity of two regimens …

… Lung cancer is the leading cause of cancer death in industrialized countries. Non-small-cell
lung cancers (NSCLC) represent more than 80% of all lung cancers. The great majority of …

… on day 1 of each cycle (induction phase), followed by iv atezolizumab or placebo according
to randomized assignment (maintenance phase), until unacceptable toxicity or disease …

Background This trial was designed to evaluate the activity and safety of ganetespib in
combination with docetaxel in advanced non-small cell lung cancer (NSCLC) and to identify …

Background NEJ002 study, comparing gefitinib with carboplatin (CBDCA) and paclitaxel (PTX;
Taxol) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) …

… In this randomized, single-center, non-comparative phase II trial, the efficacy and safety of …
-line therapy for advanced non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: …

… AENEAS was a multicenter, double-blind, randomized phase III trial conducted at 53
study sites in mainland China (Data Supplement, online only). The trial was conducted in …

… (HTRT) in limited disease (LD) small cell lung cancer (SCLC) is associated with a high response
… Group (HeCOG) performed a multicenter randomized phase II study in patients with LD …

… OAK (NCT02008227) is a randomized phase III study comparing the efficacy and safety of
… However, after the randomized phase II POPLAR study demonstrated survival benefit with …